Oxygen Production of Modified Core–Shell CuO@ZrO2 Nanocomposites by Microwave Radiation to Alleviate Cancer Hypoxia for Enhanced Chemo-Microwave Thermal Therapy
Authors:
- 4 December 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 12 (12) , 12721-12732
Abstract
There are acknowledged risks of metastasis of cancer cells and obstructing cancer treatment from hypoxia. In this work, we design a multifunctional nanocomposite for treating hypoxia based on the oxygen release capability of CuO triggered by microwave (MW). Core-shell CuO@ZrO2 nanocomposites are prepared by confining CuO nanoparticles within the cavities of mesoporous ZrO2 hollow nanospheres. The 1-butyl-3-methylimidazolium hexafluorophosphate (IL) is loaded to the CuO@ZrO2 nanocomposites for improving microwave thermal therapy (MWTT). 1-Tetradecanol (PCM) is introduced to regulate the release of chemotherapeutic drugs of Doxorubicin (DOX). Thus, the IL-DOX-PCM-CuO@ZrO2 multifunctional (IDPC@Zr) nanocomposites are obtained. Finally, IDPC@Zr nanocomposites are modified by monomethoxy polyethylene glycol sulfhydryl (mPEG-SH, 5kDa) (IDPC@Zr-PEG nanocomposites). IDPC@Zr-PEG nanocomposites can produce oxygen in the tumor microenvironment during the course of tumor treatment, thereby alleviating the hypoxic state and improving the therapeutic effect. In vivo anti-tumor experiments prove that the tumor rate is very high and the inhibition rate is 92.14%. In addition, CT imaging contrast of the nanocomposites can be enhanced due to the high atomic number of Zr. Therefore, IDPC@Zr-PEG nanocomposites can be applied for monitoring the tumor treatment process in real time. The combined therapy offers many opportunities, such as the production of oxygen from CuO nanoparticles by MW to alleviate hypoxia, the enhancement of combined treatment of MWTT and chemotherapy, and the potential application of CT imaging to visualize the treatment process, which therefore provides a promising method for clinical treatment of tumors in the future.Keywords
Funding Information
- U.S. Department of Energy (GJHZ1705)
- National Natural Science Foundation of China (81630053, 61671435)
- Chinese Academy of Sciences (GJHZ1705)
This publication has 52 references indexed in Scilit:
- Pulsed-reactant in situ studies of ceria/CuO catalysts using simultaneous XRD, PDF and DRIFTS measurementsCatalysis Today, 2014
- Hypoxia-induced tumor malignancy and drug resistance: Role of microRNAsBiomarkers and Genomic Medicine, 2014
- Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor XenograftsCancers, 2014
- Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometryProteomics, 2014
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistanceJournal of Controlled Release, 2010
- Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistryRadiotherapy and Oncology, 2008
- Hyperbaric Oxygen Therapy in the Treatment of Open Fractures and Crush InjuriesEmergency Medicine Clinics of North America, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004